Evidence map›Paper›PMID 37337950›Full record

ArticleThoracic cancer2023

Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.

Kousei Nakatsuru, Kazuya Tsubouchi, Minori Hirahata, Tadayuki Nakashima, Yuriko Takahata, Yuki Okamatsu, Yoshimasa Shiraishi, Isamu Okamoto, Taishi Harada

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kousei NakatsuruDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Kazuya TsubouchiDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.ORCID 0000-0003-0145-8745
Minori HirahataDepartment of Hematology, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Tadayuki NakashimaDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Yuriko TakahataDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Yuki OkamatsuDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Yoshimasa ShiraishiDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Isamu OkamotoDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Taishi HaradaDepartment of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.
Kyushu Hospital · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy related-acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated with a combination of atezolizumab and platinum-based chemotherapy. The patient showed progression from t-MDS to t-AML 20 months after the treatment was initiated. A combination of immune checkpoint inhibitor (ICI) and chemotherapy may increase the risk of developing therapy-related myeloid neoplasms. As the prognosis of t-AML and t-MDS is poorer than that of de novo AML and MDS, proper surveillance, follow-up, and treatment are needed throughout the course of immunotherapy.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNeoplasms, Second PrimaryHumansImmune Checkpoint InhibitorsPrognosisImmune Checkpoint Inhibitorsacute myeloid leukemiaautoimmune hemolytic anemiaimmune checkpoint inhibitorslung cancermyelodysplastic syndrome

Identifiers

PMID37337950
PMCPMC10396777
OpenAlexW4381309636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.